News

AMSBIO has further expanded its product range to help in the fight against COVID-19 with the introduction of a new range of SARS-CoV-2 antibodies and antigens to aid development of new immunoassay diagnostic kits.

New in vitro Bioactivation Liver Response Assay used HEPATOPAC model to demonstrate utility of in vitro transcriptomic signature-based strategy in preclinical DILI risk assessment


Westbury, NY – Oct. 12, 2020 – BioIVT, a leading provider of research models and services for drug and diagnostic development, today announced the publication of research describing the use of HEPATOPAC® cultures with a targeted in vitro assay to identify small molecule drugs with high potential for drug-induced liver injury (DILI).1

Stevenage Bioscience Catalyst’s new Spark Building opened its doors in January to accommodate the rapid growth of scale-up businesses within Hertfordshire’s world-class cell and gene cluster.

Systematic direct cell conversion platform published in Cell Systems


Platform measures changes in H3K4me3 histone modifications to predict optimal growth factors required to both maintain cells in culture and support conversion between cell types


EpiMOGRIFY co-developed and co-owned by Duke-NUS, Monash University and Mogrify

The Department for International Trade (DIT) has classified Stevenage, Hertfordshire, as a High Potential Opportunity (HPO) zone in recognition of its thriving cell and gene therapy cluster of national and international significance. The successful HPO nomination was made by Hertfordshire Local Enterprise Partnership (LEP) and is expected to help attract further overseas investment into the county.

• TTP Ventus Disc Pump combined with Sensirion liquid flow sensor

• Together, technologies provide exceptional liquid flow control

• New system suitable for laboratory testing and product prototyping

Click here for the October edition of eNews. 


The Biosphere, a specialist lab facility on Newcastle Helix, has welcomed yet another Newcastle University spin-out, who has developed and commercialised a prognostic test for early-stage skin cancer.

Biohazards are understandably in the spotlight again, due to COVID-19. As a health and safety consultancy specialising in the scientific sector, Bishop Simon Ltd was asked by the Institution of Occupational Safety and Health Magazine to contribute to their article “ARE YOU PREPARED FOR THE NEXT BIOHAZARD” - https://www.ioshmagazine.com/2020/09/09/are-you-prepared-next-biohazard. The article focuses on health and safety practices that organisations are applying to meet the challenges of outbreaks.

Pages